Advanced nanocarriers for optimized antioxidant therapy.

Marco Silva*

Department of Therapeutic Sciences, University of São Paulo, Brazil

Introduction

Targeted delivery systems for antioxidants have become a critical area of research, aiming to overcome limitations associated with traditional antioxidant therapies, such as poor bioavailability, rapid degradation, and non-specific distribution. These advanced strategies significantly enhance therapeutic outcomes by ensuring antioxidants reach specific sites of action, thereby mitigating oxidative stress more effectively.

Recent reviews underscore the promise of nanosystems for precise delivery of natural antioxidants. These approaches are designed to improve antioxidant stability, boost bioavailability, and facilitate cellular uptake. This leads to enhanced therapeutic efficacy, largely by reducing oxidative stress in various pathological conditions. Such advancements highlight a shift towards more targeted antioxidant interventions[1].

In the context of neurological conditions, a novel brain-targeted antioxidant delivery system has been developed for treating ischemic stroke. Studies reveal this system achieves improved brain accumulation while significantly reducing systemic exposure. This balance is vital for maximizing therapeutic effects and minimizing unwanted off-target impacts, a key consideration for delicate neurological applications[2].

Liposomal encapsulation represents another avenue for enhancing antioxidant delivery. For instance, research into quercetin, a potent antioxidant, demonstrates that when delivered via liposomes, its in-vivo pharmacokinetic profile and biodistribution are markedly altered. This modification substantially improves its bioavailability and promotes its accumulation in specific target tissues, which is essential for maximizing its therapeutic potential and antioxidant benefits[3].

Further insights into neurodegenerative diseases emphasize the need for advanced antioxidant drug delivery systems. Current developments focus on strategies to facilitate antioxidant transport across the Blood-Brain Barrier (BBB), a significant challenge in neurological drug delivery. By enhancing this passage, these systems aim to improve therapeutic efficacy and refine pharmacokinetic profiles, which is crucial for managing complex neurological conditions and counteracting oxidative damage effectively[4].

Polymer-drug conjugates offer a pathway to optimize antioxidant performance. A study involving a novel polymer-curcumin conjugate, for example, showcased a significant improvement in curcumin's bioavailability and an extended systemic circulation time in animal models. This strategic conjugation enhances curcumin's inherent antioxidant potential by improving its in vivo performance and stability[5].

Enzymatic antioxidants also benefit greatly from advanced delivery methods. Research on Superoxide Dismutase (SOD) encapsulated within mesoporous silica nanoparticles demonstrates that this specific delivery system enhances the enzyme's stability and prolongs its circulation time. This makes SOD a more viable therapeutic agent by optimizing its performance within the body and reducing premature degradation[6].

Innovative approaches, like exosome-mimetic nanovesicles, are being explored for targeted antioxidant delivery, such as in the treatment of acute kidney injury. While the primary focus remains on precise delivery and efficacy, these systems inherently refine the pharmacokinetic profile. They achieve this by concentrating antioxidants at the injury site, thereby minimizing systemic side effects and elevating local therapeutic concentrations where they are most needed[7].

Solid lipid nanoparticles have also proven effective in improving the bioavailability and antioxidant activity of compounds like curcumin. In vivo investigations clearly show substantial improvements in curcumin's pharmacokinetic parameters, leading to superior antioxidant effects compared to its free form. This addresses critical challenges related to curcumin's solubility and stability, paving the way for better therapeutic outcomes[8].

The use of liposomes extends to delivering other antioxidant enzymes, such as catalase. In an inflammatory bowel disease model, catalase-loaded liposomes demonstrated improved enzyme stability and extended circulation time. This translates to enhanced antioxidant effects directly at the site of inflammation, underscoring the potential of such systems for localized treatment[9].

***Correspondence to:** Marco Silva, Department of Therapeutic Sciences, University of São Paulo, Brazil. E-mail: marco.silva@pharmascience.br

Received: 05-May-2025, Manuscript No. AAJPTR-25-202; **Editor assigned:** 07-May-2025, Pre QC No. AAJPTR-25-202 *(PQ)*; **Reviewed:** 27-May-2025, QC No. AAJPTR-25-202; **Revised:** 05-Jun-2025, Manuscript No. AAJPTR-25-202 *(R)*; **Published:** 16-Jun-2025, DOI: 10.35841/aajptr-9.3.202

Citation: Silva M. Advanced nanocarriers for optimized antioxidant therapy. J Pharmacol Ther Res. 2025;09(03):202.

Finally, smart nanogels are being developed for the controlled release of antioxidants in inflammatory conditions. These advanced delivery platforms, while primarily designed for targeted and controlled release, inherently optimize pharmacokinetic profiles. They achieve this by prolonging circulation, improving overall bioavailability, and concentrating the active antioxidant at diseased sites, ultimately boosting therapeutic efficacy in a precise manner[10].

Conclusion

Research into antioxidant delivery systems consistently shows significant advancements aimed at overcoming the limitations of traditional therapies. Various nanocarriers, including nanosystems, liposomes, polymer-drug conjugates, mesoporous silica nanoparticles, solid lipid nanoparticles, exosome-mimetic nanovesicles, and smart nanogels, are being ingeniously developed to profoundly improve the pharmacokinetic profiles of antioxidants. These innovative approaches are designed to enhance antioxidant stability, substantially increase bioavailability, and facilitate highly targeted delivery to specific tissues. This includes critical sites like the brain for ischemic stroke, the kidneys for acute injury, and localized areas of inflammation. Key examples highlight liposomes significantly improving quercetin and catalase delivery, while polymer conjugates expertly enhance curcumin's performance and solid lipid nanoparticles boost curcumin's bioavailability even further. Moreover, systems engineered for Superoxide Dismutase (SOD) demonstrate remarkably extended circulation times and improved in vivo performance. The overarching goal across these diverse strategies is to optimize therapeutic efficacy by precisely concentrating antioxidants at disease sites, thereby minimizing systemic exposure and mitigating oxidative stress far more effectively. These collective studies underscore a robust, ongoing push towards more precise and potent antioxidant interventions for a wide array of pathological conditions, ultimately promising better patient outcomes through intelligent drug design and advanced delivery mechanisms.

References

1. Alireza S, Sahar M, Parmis K. Nanosystems for targeted delivery of natural antioxidants: an updated overview. *Eur J Pharm Sci.* 2024;193:106560.
2. Ying Z, Can W, Yang L. Pharmacokinetics and tissue distribution of a novel brain-targeted antioxidant drug delivery system for ischemic stroke. *Int J Pharm.* 2020;588:119799.
3. Haiyan L, Zhenzhen C, Fang Z. Pharmacokinetics and biodistribution of quercetin-loaded liposomes in vivo: *A comprehensive study. Nanomedicine* (Auck). 2021;35:102377.
4. Bing L, Yan X, *Xiaole M. Current advances in antioxidant drug delivery systems for neurodegenerative diseases. J Control Release.* 2021;335:361-379.
5. Yan M, Teng L, Chuanhong Z. Pharmacokinetics and antioxidant activity of a novel polymer-drug conjugate of curcumin in rats. *Drug Deliv.* 2020;27:1184-1193.
6. Chao Z, Biao L, *Xue Z. Pharmacokinetic study of a novel antioxidant enzyme SOD encapsulated in mesoporous silica nanoparticles. J Mater Chem B.* 2019;7:4403-4410.
7. Zehong H, Bo Q, Wei L. Exosome-mimetic nanovesicles for targeted delivery of antioxidants to alleviate oxidative stress in acute kidney injury. *Biomater Sci.* 2023;11:6876-6889.
8. Mounica P, Bhaskaran S, Chandana V. Enhanced bioavailability and antioxidant activity of curcumin-loaded solid lipid nanoparticles: *In vitro and in vivo studies. Environ Sci Pollut Res.* 2019;26:36622-36637.
9. Suyeon H, Taejun L, Euihwan L. Pharmacokinetics and therapeutic efficacy of catalase-loaded liposomes in a murine model of inflammatory bowel disease. *Pharmaceutics.* 2022;14:1020.
10. Sathish P, Vignesh K, *Saravanan S. Smart nanogels for controlled release and enhanced delivery of antioxidants in inflammation. J Drug Deliv Sci Technol.* 2022;72:103764.

Citation: *Silva M. Advanced nanocarriers for optimized antioxidant therapy. J Pharmacol Ther Res. 2025;09(03):202.*